Category:Angiotensin receptor blocker
From Ganfyd
Current revision (19:54, 16 January 2010) (view source) (antidementia properties) |
|||
| Line 13: | Line 13: | ||
==History== | ==History== | ||
| - | See [[:category:angiotensin converter enzyme inhibitor|ACE inhibitors]]. The octapeptide angiotensin II receptor blocker saralasin was actually demonstrated to work in man in the mid 1970s, with publications from 1975, before the first ACE inhibitor work in man. This is still a very active area of research, both public and undisclosed for commercial reasons. There appear to be several receptors for angiotension II and the area of research even extends into a possible role for some angiotension II blockers as antibiotics<ref>[http://www.joimr.org/phorum/read.php?f=2&i=53&t=53 Marshall TG, Fenter B, Marshall FE. Putative Antibacterial Mechanisms for Angiotensin II Receptor Blockers. J Independent Medical Rsearch 2004 accessed 18th March 2006]</ref> | + | See [[:category:angiotensin converter enzyme inhibitor|ACE inhibitors]]. The octapeptide angiotensin II receptor blocker saralasin was actually demonstrated to work in man in the mid 1970s, with publications from 1975, before the first ACE inhibitor work in man. This is still a very active area of research, both public and undisclosed for commercial reasons. There appear to be several receptors for angiotension II and the area of research even extends into a possible role for some angiotension II blockers as antibiotics<ref>[http://www.joimr.org/phorum/read.php?f=2&i=53&t=53 Marshall TG, Fenter B, Marshall FE. Putative Antibacterial Mechanisms for Angiotensin II Receptor Blockers. J Independent Medical Rsearch 2004 accessed 18th March 2006]</ref>. Accordingly they are not quite the same as ACE inhibitors and may have unique beneficial properties as in preventing dementia<ref>[http://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=20068258 Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ (Clinical research ed.). 2010; 340:b5465.]<small>(Epub) </small></ref>. |
==Clinical Differences== | ==Clinical Differences== | ||
These do appear to exist, with for example the evidence for use in non specific heart failure being strongest for [[candesartan]], diabetic renal failure strongest for [[irbesartan]]<ref>[http://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=20030566 Bramlage P, Schindler C. Differences in pharmacology and their translation into differences in clinical efficacy - a comparison of the renin angiotensin blocking agents irbesartan and losartan. Expert opinion on pharmacotherapy. 2009 Dec 23.]<small>(Epub ahead of print) </small><small>([http://dx.doi.org/10.1517/14656560903512962 Link to article] – subscription may be required.)</small></ref> and gout strongest for [[losartan]]<ref>[http://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=18670416 Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K, Sonoyama K, Sugihara S, Igawa O, Hosoya T, Ohtahara A, Shigamasa C, Yamamoto Y, Ninomiya H, Hisatome I. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. American journal of hypertension. 2008 Oct; 21(10):1157-62.]<small>([http://dx.doi.org/10.1038/ajh.2008.245 Link to article] – subscription may be required.)</small></ref>. | These do appear to exist, with for example the evidence for use in non specific heart failure being strongest for [[candesartan]], diabetic renal failure strongest for [[irbesartan]]<ref>[http://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=20030566 Bramlage P, Schindler C. Differences in pharmacology and their translation into differences in clinical efficacy - a comparison of the renin angiotensin blocking agents irbesartan and losartan. Expert opinion on pharmacotherapy. 2009 Dec 23.]<small>(Epub ahead of print) </small><small>([http://dx.doi.org/10.1517/14656560903512962 Link to article] – subscription may be required.)</small></ref> and gout strongest for [[losartan]]<ref>[http://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=18670416 Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K, Sonoyama K, Sugihara S, Igawa O, Hosoya T, Ohtahara A, Shigamasa C, Yamamoto Y, Ninomiya H, Hisatome I. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. American journal of hypertension. 2008 Oct; 21(10):1157-62.]<small>([http://dx.doi.org/10.1038/ajh.2008.245 Link to article] – subscription may be required.)</small></ref>. | ||
Current revision
Contents |
Introduction
This class of drugs block the angiotensin ii receptor in the renin-angiotensin system and have many properties in common with ACE inhibitors. However, unlike ACE inhibitors, they do not inhibit the breakdown of bradykinin and other kinins, and thus do not appear to cause the persistent dry cough which commonly complicates ACE inhibitor therapy. They are therefore a useful alternative for patients who have to discontinue an ACE inhibitor because of persistent cough. They are second choice to ACE inhibitors both because of cost and more overall side-effects[1].
History
See ACE inhibitors. The octapeptide angiotensin II receptor blocker saralasin was actually demonstrated to work in man in the mid 1970s, with publications from 1975, before the first ACE inhibitor work in man. This is still a very active area of research, both public and undisclosed for commercial reasons. There appear to be several receptors for angiotension II and the area of research even extends into a possible role for some angiotension II blockers as antibiotics[2]. Accordingly they are not quite the same as ACE inhibitors and may have unique beneficial properties as in preventing dementia[3].
Clinical Differences
These do appear to exist, with for example the evidence for use in non specific heart failure being strongest for candesartan, diabetic renal failure strongest for irbesartan[4] and gout strongest for losartan[5].
Indications
Group Side effects
Angioneurotic oedema whch is a recognised occasional adverse reaction to ACE blockers has also been reported with ARBs. It is less than certain how likely exhibiting an ARB in a patient who had to cease their ACE is to cause the same trouble. An estimate is that the risk is 1 in 3.
Group Interactions
Special advice
References
- ↑ McMurray JJ. ACE Inhibitors in Cardiovascular Disease -- Unbeatable? The New England journal of medicine. 2008 Apr 10; 358(15):1615-6.(Link to article – subscription may be required.)
- ↑ Marshall TG, Fenter B, Marshall FE. Putative Antibacterial Mechanisms for Angiotensin II Receptor Blockers. J Independent Medical Rsearch 2004 accessed 18th March 2006
- ↑ Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ (Clinical research ed.). 2010; 340:b5465.(Epub)
- ↑ Bramlage P, Schindler C. Differences in pharmacology and their translation into differences in clinical efficacy - a comparison of the renin angiotensin blocking agents irbesartan and losartan. Expert opinion on pharmacotherapy. 2009 Dec 23.(Epub ahead of print) (Link to article – subscription may be required.)
- ↑ Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K, Sonoyama K, Sugihara S, Igawa O, Hosoya T, Ohtahara A, Shigamasa C, Yamamoto Y, Ninomiya H, Hisatome I. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. American journal of hypertension. 2008 Oct; 21(10):1157-62.(Link to article – subscription may be required.)
Pages in category "Angiotensin receptor blocker"
The following 8 pages are in this category, out of 8 total.
AC |
EIL |
OTV |
